Fluvastatin accelerates re-endothelialization impaired by local sirolimus treatment

European Journal of Pharmacology

Volumn 612, Issue 1-3, 2009, Pages 87-92

  Fukuda, Daiju ^a   Enomoto, Soichiro ^a   Shirakawa, Ibuki ^a   Nagai, Ryozo ^a   Sata, Masataka ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Re endothelialization; Sirolimus; Statin; Thrombosis; Vascular injury

Indexed keywords

CD31 ANTIGEN; DIMETHYL SULFOXIDE; DRUG VEHICLE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUINDOSTATIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL REGENERATION; CONTROLLED STUDY; DRUG ELUTING STENT; ENDOTHELIALIZATION; ENDOTHELIUM LESION; EPITHELIZATION; MOUSE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; THROMBOSIS;

ANIMALS; ANTIGENS, CD31; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FATTY ACIDS, MONOUNSATURATED; FEMALE; FEMORAL ARTERY; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INDOLES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RANDOM ALLOCATION; SIROLIMUS; TIME FACTORS; TUNICA INTIMA; TUNICA MEDIA;

EID: 65549166977     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.04.006     Document Type: Article

References (33)

1. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., Witzenbichler B., Schatteman G., and Isner J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
2. Awata M., Kotani J., Uematsu M., Morozumi T., Watanabe T., Onishi T., Iida O., Sera F., Nanto S., Hori M., and Nagata S. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation 116 (2007) 910-916
3. Dimmeler S., Aicher A., Vasa M., Mildner-Rihm C., Adler K., Tiemann M., Rutten H., Fichtlscherer S., Martin H., and Zeiher A.M. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest. 108 (2001) 391-397
4. Fajadet J., Morice M.C., Bode C., Barragan P., Serruys P.W., Wijns W., Constantini C.R., Guermonprez J.L., Eltchaninoff H., Blanchard D., Bartorelli A., Laarman G.J., Perin M., Sousa J.E., Schuler G., Molnar F., Guagliumi G., Colombo A., Ban Hayashi E., and Wulfert E. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation 111 (2005) 1040-1044
5. Finn A.V., Nakazawa G., Joner M., Kolodgie F.D., Mont E.K., Gold H.K., and Virmani R. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1500-1510
6. Friedrich E.B., Walenta K., Scharlau J., Nickenig G., and Werner N. CD34-/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ. Res. 98 (2006) e20-e25
7. Fukuda D., Sata M., Tanaka K., and Nagai R. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation 111 (2005) 926-931
8. Hofma S.H., van der Giessen W.J., van Dalen B.M., Lemos P.A., McFadden E.P., Sianos G., Ligthart J.M., van Essen D., de Feyter P.J., and Serruys P.W. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur. Heart J. 27 (2006) 166-170
9. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., Airoldi F., Chieffo A., Montorfano M., Carlino M., Michev I., Corvaja N., Briguori C., Gerckens U., Grube E., and Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J.A.M.A. 293 (2005) 2126-2130
10. Ii M., and Losordo D.W. Statins and the endothelium. Vasc. Pharmacol. 46 (2007) 1-9
11. Jabs A., Gobel S., Wenzel P., Kleschyov A.L., Hortmann M., Oelze M., Daiber A., and Munzel T. Sirolimus-induced vascular dysfunction. Increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation. J. Am. Coll. Cardiol. 51 (2008) 2130-2138
12. Jeremias A., Sylvia B., Bridges J., Kirtane A.J., Bigelow B., Pinto D.S., Ho K.K., Cohen D.J., Garcia L.A., Cutlip D.E., and Carrozza Jr. J.P. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 109 (2004) 1930-1932
13. Kong D., Melo L.G., Mangi A.A., Zhang L., Lopez-Ilasaca M., Perrella M.A., Liew C.C., Pratt R.E., and Dzau V.J. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 109 (2004) 1769-1775
14. Kotani J., Awata M., Nanto S., Uematsu M., Oshima F., Minamiguchi H., Mintz G.S., and Nagata S. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J. Am. Coll. Cardiol. 47 (2006) 2108-2111
15. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N. Engl. J. Med. 356 (2007) 1009-1019
16. Lamb F.S., and Barna T.J. The endothelium modulates the contribution of chloride currents to norepinephrine-induced vascular contraction. Am. J. Physiol. 275 (1998) H161-H168
17. Luscher T.F., and Noll G. The pathogenesis of cardiovascular disease: role of the endothelium as a target and mediator. Atherosclerosis 118 Suppl (1995) S81-S90
18. Marks A.R. Sirolimus for the prevention of in-stent restenosis in a coronary artery. N. Engl. J. Med. 349 (2003) 1307-1309
19. McFadden E.P., Stabile E., Regar E., Cheneau E., Ong A.T., Kinnaird T., Suddath W.O., Weissman N.J., Torguson R., Kent K.M., Pichard A.D., Satler L.F., Waksman R., and Serruys P.W. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 (2004) 1519-1521
20. Meier P., Zbinden R., Togni M., Wenaweser P., Windecker S., Meier B., and Seiler C. Coronary collateral function long after drug-eluting stent implantation. J. Am. Coll. Cardiol. 49 (2007) 15-20
21. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O Shaughnessy C., Caputo R.P., Kereiakes D.J., Williams D.O., Teirstein P.S., Jaeger J.L., and Kuntz R.E. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349 (2003) 1315-1323
22. Muldowney III J.A., Stringham J.R., Levy S.E., Gleaves L.A., Eren M., Piana R.N., and Vaughan D.E. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 400-406
23. Okabe M., Ikawa M., Kominami K., Nakanishi T., and Nishimune Y. 'Green mice' as a source of ubiquitous green cells. FEBS Lett. 407 (1997) 313-319
24. Ross R. Atherosclerosis-an inflammatory disease. N. Eng. J. Med. 340 (1999) 115-126
25. Sata M., Kakoki M., Nagata D., Nishimatsu H., Suzuki E., Aoyagi T., Sugiura S., Kojima H., Nagano T., Kangawa K., Matsuo H., Omata M., Nagai R., and Hirata Y. Adrenomedullin and nitric oxide inhibit human endothelial cell apoptosis via a cyclic GMP-independent mechanism. Hypertension 36 (2000) 83-88
26. Sata M., Saiura A., Kunisato A., Tojo A., Okada S., Tokuhisa T., Hirai H., Makuuchi M., Hirata Y., and Nagai R. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat. Med. 8 (2002) 403-409
27. Serruys P.W., Degertekin M., Tanabe K., Abizaid A., Sousa J.E., Colombo A., Guagliumi G., Wijns W., Lindeboom W.K., Ligthart J., de Feyter P.J., and Morice M.C. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 106 (2002) 798-803
28. Stone G.W., Moses J.W., Ellis S.G., Schofer J., Dawkins K.D., Morice M.C., Colombo A., Schampaert E., Grube E., Kirtane A.J., Cutlip D.E., Fahy M., Pocock S.J., Mehran R., and Leon M.B. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med. 356 (2007) 998-1008
29. Togni M., Windecker S., Cocchia R., Wenaweser P., Cook S., Billinger M., Meier B., and Hess O.M. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J. Am. Coll. Cardiol. 46 (2005) 231-236
30. Walter D.H., Zeiher A.M., and Dimmeler S. Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells. Coron. Artery Dis. 15 (2004) 235-242
31. Weis M., Heeschen C., Glassford A.J., and Cooke J.P. Statins have biphasic effects on angiogenesis. Circulation 105 (2002) 739-745
32. Werner N., Priller J., Laufs U., Endres M., Bohm M., Dirnagl U., and Nickenig G. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1567-1572
33. Wolfrum S., Jensen K.S., and Liao J.K. Endothelium-dependent effects of statins. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 729-736